Investor · 1 deal
Every published round US Cystic Fibrosis Foundation took part in, and every parcel of existing shares it bought off another holder. Deals we hold but haven't published yet are not counted.
| Company | Stage | Announced | Amount | Role | Alongside | Sources |
|---|---|---|---|---|---|---|
| Respirion | Grant | 15 Mar 2019 | ≤US$3m (≤$4.2m) | Lead | Brandon BioCatalyst portfolio, Brandon Capital portfolio |
Companies US Cystic Fibrosis Foundation has backed in a published round, and companies whose existing shares it bought off another holder.
| Company | What it does | First invested | Rounds | Led |
|---|---|---|---|---|
| Respirion | 15 Mar 2019, Grant | 1 | 1 |
Fund closes reported for US Cystic Fibrosis Foundation, as distinct from the investments it has made.
Companies US Cystic Fibrosis Foundation has backed that another company then bought. An exit for the holding, not a deal US Cystic Fibrosis Foundation did.
Stories naming US Cystic Fibrosis Foundation. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Brandon Capital's blog profiles Respirion, interviewing founders Barry Clements and Matt Callahan plus investment manager Helga Mikkelsen about the company's inhaled cystic fibrosis therapy, now in a Phase 2a trial.
A Telethon Kids spin-out backed by Brandon Capital has begun trials in the US and Australia of RSP-1502, an inhaled antibiotic booster for cystic fibrosis lung infections, after strong early results in WA patients.
A Telethon Kids offshoot, Respirion Pharmaceuticals, is trialling its antibiotic-booster therapy RSP-1502 in the US and Australia, with backing from Brandon Capital and an American cystic fibrosis foundation.
Techboard's quarterly report shows record national early-stage funding, driven by PEXA's sale and Airwallex's raise, while Western Australian funding stayed subdued, led by Respiron Pharmaceuticals, several ASX placements, grants and one acquisition.
The MRCF Biomedical Translation Fund has launched Respirion Pharmaceuticals, a Perth biotech developing an inhaled antibiotic for cystic fibrosis, committing up to A$20 million, with up to US$3 million from the CF Foundation.